BridgeBio Oncology Therapeutics, Inc. Common Stock

Shares of BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) are trading at $3.59. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest BBOT is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 5, 2026.